TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04978727

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years
Description: 500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients \< 30 kg, and 100 mcg for patients ≥ 30 kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years
Description: 500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients \< 30 kg, and 100 mcg for patients ≥ 30 kg.
Study: NCT06509282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concurrent training
Description: Protocol:~Duration: 6 weeks. Frequency: 3 times a week. Type: Concurrent. This consists of a combination of aerobic exercise and muscular resistance exercise.~Details of the type of exercise:~Aerobic exercise:~Participants will perform 5-10 intervals per session of walking or jogging at a moderate to high intensity, with a rating of 5 to 10 points on the modified Borg scale of 1-10 points. Each interval will consist of 1 minute of walking or jogging, followed by 2 minutes of inactive pause.~Muscular resistance exercise:~Participants will perform concentric and eccentric and/or isometric contractions for 1 minute at an intensity of 5-10 according to the OMNI-RES scale. The rest period will last 2 minutes, and each exercise will be repeated 3 times. Three exercises per session will be performed: squats, push-ups, and plank.~Pharmacological treatment:~Participants will be asked to maintain their lifestyle, including taking prescribed medication as usual.
Study: NCT05527808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg ,intravenous injection ,Q3W 2-4 cycles
Study: NCT04978727

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years
Description: 500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients \< 30 kg, and 100 mcg for patients ≥ 30 kg.
Study: NCT05949411

Intervention type: OTHER
Group type: OTHER
Intervention: Screening visit
Description: Subjects will be invited to perform the screening visit to sign the informed consent and then to ensure that they are able to participate in this study.

Intervention type: OTHER
Group type: OTHER
Intervention: Lactulose test
Description: Fasted subjects (at least 10 hours) will receive on oral load of 10 g of lactulose. Then, exhaled H2 will be measured every 30 minutes during 4 hours.

Intervention type: OTHER
Group type: OTHER
Intervention: Administration of standardized meals with characterized dietary fiber content
Description: Subjects will receive standardized breakfasts and lunches characterized in terms of dietary fiber content. Urine, saliva, feces samples will be collected. Breath test and gastrointestinal symptoms will be followed during maximum 8h. Subjects will also complete SF36 questionnaire, food diary and stool/transit questionnaire.

Intervention type: OTHER
Group type: OTHER
Intervention: Administration of standardized meals with characterized dietary fiber content
Description: Subjects will receive standardized breakfasts and lunches characterized in terms of dietary fiber content. Urine, saliva, feces samples will be collected. Breath test and gastrointestinal symptoms will be followed during maximum 8h. Subjects will also complete SF36 questionnaire, food diary and stool/transit questionnaire.

Intervention type: OTHER
Group type: OTHER
Intervention: Administration of standardized meals with characterized dietary fiber content
Description: Subjects will receive standardized breakfasts and lunches characterized in terms of dietary fiber content. Urine, saliva, feces samples will be collected. Breath test and gastrointestinal symptoms will be followed during maximum 8h. Subjects will also complete SF36 questionnaire, food diary and stool/transit questionnaire.
Study: NCT06779188

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: TMS (in the form of theta burst stimulations) will be delivered over Supplementary Motor Area while the subject is seated in the Treatment group. TMS is capable to induce neuroplastic facilitatory changes in the brain that last beyond the duration of stimulation. TMS will be delivered once daily, 5 days per week, for 4 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation Sham
Description: Sham TMS will be delivered in the sham group using a sham coil once daily, 5 days per week, for 4 weeks.
Study: NCT06779396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The triamcinolone acetonide plus ropivacaine group
Description: The solution prepared comprised a mixture of 20mL of 0.2% ropivacaine(40mg) with 4 mg of triamcinolone acetonide. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The ropivacaine group
Description: The local infiltration solution containing 20mg of 1% ropivacaine. The total volume is 20 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
Study: NCT05257460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop using ultra-rapid insulin lispro
Description: Hybrid closed-loop using ultra-rapid insulin lispro

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid closed-loop using standard insulin lispro
Description: Hybrid closed-loop using standard insulin lispro
Study: NCT04461730

Intervention type: DEVICE
Intervention: deep brain stimulation
Description: Behavioral and electroencephalographic responses will be compared on and off deep brain stimulation

Intervention type: DEVICE
Intervention: deep brain stimulation
Description: Behavioral and electroencephalographic responses will be compared on and off deep brain stimulation

Intervention type: DEVICE
Intervention: deep brain stimulation
Description: Behavioral and electroencephalographic responses will be compared on and off deep brain stimulation

Intervention type: DEVICE
Intervention: deep brain stimulation
Description: Behavioral and electroencephalographic responses will be compared on and off deep brain stimulation
Study: NCT05821114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head elevation_H
Description: High flow_Head-elevation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supine_H
Description: High flow_Supine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Head elevation_L
Description: Low flow_head elevation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supine_L
Description: Low flow_supine
Study: NCT06036771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Voice-activated Intelligent Personal Assistant (VIPA)
Description: Apple HomePod mini is selected as the intervention medium of this study as it is the only available smart speaker that supports Cantonese
Study: NCT04982198

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ROSA assisted TKA
Description: Robotic assisted total knee arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ROSA assisted TKA
Description: Robotic assisted total knee arthroplasty
Study: NCT06048445

Intervention type: DEVICE
Intervention: intraoperative plancement of Biliary Drainage Stent
Description: plancement of Biliary Drainage Stent in liver transplantation of pediatric patients
Study: NCT04953468

Intervention type: DIAGNOSTIC_TEST
Intervention: expression level of ANXA2 protein
Description: The expression level of ANXA2 protein in glioma and PTBE was detected by immunohistochemistry

Intervention type: DIAGNOSTIC_TEST
Intervention: expression level of ANXA2 protein
Description: The expression level of ANXA2 protein in glioma and PTBE was detected by immunohistochemistry

Intervention type: DIAGNOSTIC_TEST
Intervention: expression level of ANXA2 protein
Description: The expression level of ANXA2 protein in glioma and PTBE was detected by immunohistochemistry
Study: NCT06012019

Intervention type: OTHER
Intervention: Biological sampling in Periodontitis Case
Description: Periodontal bacteria, gingival fluid, unstimulated saliva and blood collection;~J+7 : tooth extraction : gingival explant sampling~J+15 : Healing control

Intervention type: OTHER
Intervention: Biological sampling in Gingivitis Case
Description: Periodontal bacteria, gingival fluid, unstimulated saliva and blood collection;~J+7 : tooth extraction or pre-prosthetic periodontal surgeries : gingival explant sampling~J+15 : Healing control

Intervention type: OTHER
Intervention: Biological sampling in Control Case
Description: Periodontal bacteria, gingival fluid, unstimulated saliva and blood collection;~J+7 : tooth extraction or pre-prosthetic periodontal surgeries : gingival explant sampling~J+15 : Healing control
Study: NCT06595823

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betadine
Description: To compare between Betadine (10%) and saline (0.9%) in swapping of subcutaneous tissue for prevention of surgical site infection after primary elective caesarian section.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betadine
Description: To compare between Betadine (10%) and saline (0.9%) in swapping of subcutaneous tissue for prevention of surgical site infection after primary elective caesarian section.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Betadine
Description: To compare between Betadine (10%) and saline (0.9%) in swapping of subcutaneous tissue for prevention of surgical site infection after primary elective caesarian section.
Study: NCT05852158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin 2 GM Injection
Description: Single pre-op dose of 2g IV cefazolin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin Injection
Description: Pre-op dose of 2g IV cefazolin along with 3 post-op doses of 2g IV cefazolin every 8 hours
Study: NCT06605833

Intervention type: DIAGNOSTIC_TEST
Intervention: Lead ECG
Description: Participants will undergo a standard 12 lead ECG in order to record the electrical activity of the heart. This typically takes a few minutes and the ECG is read by a cardiologist~This is a Standard of Care test being performed at a non Standard of Care timepoint

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic Echocardiogram
Description: A transthoracic echocardiogram will be performed in accordance to standard British Society of Echocardiography guidelines. This will involve undertaking an ultrasound scan of the participant's heart with ultrasound jelly to obtain information including left ventricular function and valvular function.~This is a Standard of Care test being performed at a non Standard of Care timepoint

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: A cardiac MRI scan will be performed in order to assess the morphology and function of the heart in accordance with international guidelines. Data that will be derived includes biventricular volumes and function and myocardial strain data.~This is a Standard of Care test being performed at a non Standard of Care timepoint

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Biomarker Screening
Description: * Cardiac Troponin I,~* NTproBNP\],~* lipid profile,~* HbA1c~* ferritin~These are Standard of Care tests being performed at a non Standard of Care timepoint

Intervention type: OTHER
Intervention: Basic Observations
Description: * Heart rate~* Blood pressure~* Oxygen SAT~* Respiratory rate~These are Standard of Care observations being performed at a non Standard of Care timepoint
Study: NCT06662162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-Lumen AMD
Description: i-Lumen AMD transpalpebral microcurrent stimulation system

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: i-Lumen AMD
Description: i-Lumen AMD transpalpebral microcurrent stimulation system
Study: NCT06605612

Intervention type: DIAGNOSTIC_TEST
Intervention: FBIndex
Description: There will be no intervention.

Intervention type: DIAGNOSTIC_TEST
Intervention: FBIndex
Description: There will be no intervention.
Study: NCT06605586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasquinimod
Description: treatment with tasquinimod capsules once daily
Study: NCT06607952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scenario-based case videos teaching protocol
Description: Students in the experimental group will receive a new teaching method of scenario-based case video interventions. These videos cover five key scenarios: Triage, SDH and ETTC, AMI and D2B, COPD AE and TOCC, and Sepsis and the CVC Procedure.~This teaching method is grounded in experiential learning theory and critical thinking strategies, designed to guide students in learning emergency nursing through video experiences. In each class, the instructor will first introduce the foundational concepts of emergency nursing for each system. Students will then watch a 15-minute scenario-based case video. Afterward, the instructor will facilitate a 15-minute discussion using reflection sheets to promote experiential learning and critical

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional lecture-based teaching method
Description: Students in the control group will receive traditional lecture-based instruction on the five topics: Triage, SDH and ETTC , AMI and D2B , COPD AE and TOCC , and Sepsis and the CVC Procedure. During the lectures, the instructor will encourage students to ask questions and engage in discussions to enhance understanding.
Study: NCT05233111

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Prolonged Exposure Therapy
Description: Brief PE will include 3 therapy sessions, each lasting approximately 60 minutes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: This may include an evaluation by a licensed psychologist and continued follow-up psychotherapy as needed. Treatment as usual participants will have follow-up assessments at 1, 3, and 6 months.
Study: NCT06500208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab combined with nab-paclitaxel, epirubicin and cyclophosphamide
Description: Adebrelimab 1200mg i.v. q3w combined with nab-paclitaxel 100mg/m2 qw\*12w followed by epirubicin 90mg/m2 and cyclophosphamide 600mg/m2 q3w for 4 cycles
Study: NCT04953468

Intervention type: DIAGNOSTIC_TEST
Intervention: expression level of ANXA2 protein
Description: The expression level of ANXA2 protein in glioma and PTBE was detected by immunohistochemistry
Study: NCT06508125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cross-linked hyaluronic acid
Description: cross-linked hyaluronic acid injection with physical therapy
Study: NCT06608667

Intervention type: DEVICE
Intervention: The study was retrospective and did not involve the application of interventions
Description: The study was retrospective and did not involve the application of interventions

Intervention type: DEVICE
Intervention: The study was retrospective and did not involve the application of interventions
Description: The study was retrospective and did not involve the application of interventions
Study: NCT06608654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endoscope application
Description: Intrauterine bronchoscopy application for fetal distress during labor
Study: NCT06608056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pain management after surgery
Description: Patients in Group A received injection tramadol 50mg intravenously every 8 hours following surgery. Patients in Group B received injection ketorolac 30mg intravenously every 8 hours following surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pain management after surgery
Description: Patients in Group A received injection tramadol 50mg intravenously every 8 hours following surgery. Patients in Group B received injection ketorolac 30mg intravenously every 8 hours following surgery.
Study: NCT06606561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NANOVAE - Acellular Allogenic Human Amniotic Fluid (hAF)
Description: A total of 24 subjects meeting all inclusion/exclusion criteria will be divided into two groups. Group 1 will be an open-label lead-in phase. Group 2 will be a randomized, double-blinded, placebo-controlled cohort. Group 1 will receive one dose of 2ml of NANOVAE, and Group 2, in a randomized and double-blinded fashion, will receive two doses of 2ml NANOVAE. Neither the patients nor the researchers will know who is getting the placebo and who is getting the NANOVAE; only the product manufacturing staff will be unblinded. The ratio of placebo to NANOVAE is 1:1 for a total of 16 subjects in Group 2. Only the knee with the more severe symptoms of OA will be treated. The allogenic-HAF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NANOVAE - Acellular Allogenic Human Amniotic Fluid (hAF)
Description: A total of 24 subjects meeting all inclusion/exclusion criteria will be divided into two groups. Group 1 will be an open-label lead-in phase. Group 2 will be a randomized, double-blinded, placebo-controlled cohort. Group 1 will receive one dose of 2ml of NANOVAE, and Group 2, in a randomized and double-blinded fashion, will receive two doses of 2ml NANOVAE. Neither the patients nor the researchers will know who is getting the placebo and who is getting the NANOVAE; only the product manufacturing staff will be unblinded. The ratio of placebo to NANOVAE is 1:1 for a total of 16 subjects in Group 2. Only the knee with the more severe symptoms of OA will be treated. The allogenic-HAF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% Sodium Chloride Injection, USP
Description: In lieu of AF, the saline for injection will be used as a placebo. Vials acquired from the manufacturer is pipetted into glass vials, stoppered, capped, placed in labeled header foil pouches, and sealed. These are transferred to a quarantine freezer to await post-production testing.
Study: NCT06662097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevonescein
Description: Bevonescein is a sterile solution that is intravenously administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevonescein
Description: Bevonescein is a sterile solution that is intravenously administered
Study: NCT06604936

Intervention type: OTHER
Intervention: Fibromyalgia group
Description: Demographic information (age, height, weight, occupation, medication, smoking) of the individuals who agreed to participate in the study will be recorded. Then, static and dynamic core endurance tests will be performed to evaluate core endurance. Static core endurance tests will include side bridge test, trunk flexion test, trunk extension test and prone bridge test. Modified push-ups and sit-ups tests will be performed as dynamic core endurance tests. Functional status of the patients will be evaluated with the Fibromyalgia Impact Questionnaire. Static and dynamic balance assessment will be evaluated using the HUR BTG4 Balance Master System and Berg Balance Scale.

Intervention type: OTHER
Intervention: Healthy group
Description: Demographic information (age, height, weight, occupation, medication, smoking) of the individuals who agreed to participate in the study will be recorded. Then, static and dynamic core endurance tests will be performed to evaluate core endurance. Static core endurance tests will include side bridge test, trunk flexion test, trunk extension test and prone bridge test. Modified push-ups and sit-ups tests will be performed as dynamic core endurance tests. Static and dynamic balance assessment will be evaluated using the HUR BTG4 Balance Master System and Berg Balance Scale.
Study: NCT06606678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: supervised exercise training; twice a week for 12 months
Study: NCT06605729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-learning
Description: The content of this e-learning is based on most recent scientific knowledge and guidelines about the management of chronic pain and physical activity and on behavioral change. Four themes are presented: chronic pain, physical activity and chronic pain, specific populations and behavior change.
Study: NCT06606808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab-800CW 4.5 mg
Description: Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab-800CW 15 mg
Description: Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab-800CW 25 mg
Description: Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab-800CW optimal dose
Description: Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
Study: NCT06608914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate
Description: Nandrolone will be administered to the testosterone group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline will be administered to the saline group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.